Hoffmann-La Roche: Lymphoma, Follicular trials
The registry lists 22 Lymphoma, Follicular studies with Hoffmann-La Roche as lead sponsor. 0 are open to participants now and 16 have results posted.
Phase 1 9Phase 2 8Phase 3 3Phase 4 1No phase 8(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- An Open-Label, Multicenter Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Combination With Tiragolumab With or Without Atezolizumab in Participants With B-Cell Non-Hodgkin LymphomaTerminatedNCT05315713Phase 1/2Results posted
- Untreated FolliculaR Lymphoma Treated With OBinituzumAb in a Non-interventional Study (URBAN)CompletedNCT04034056Results posted
- An Open-Label, Single Arm Study of Obinutuzumab Short Duration Infusion in Patients With Previously Untreated Advanced Follicular LymphomaCompletedNCT03817853Phase 4Results posted
- A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03135262Phase 1/2Results posted
- A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular LymphomaCompletedNCT02631577Phase 1/2Results posted
- A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02600897Phase 1/2Results posted
- A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02596971Phase 1/2Results posted
- A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular LymphomaCompletedNCT02569996Phase 3Results posted
- Non-Interventional Study to Examine Rituximab Treatment in Follicular Lymphoma ParticipantsCompletedNCT02536664Results posted
- A Study of Rituximab in Combination With Chemotherapy in Relapsed/Refractory Follicular LymphomaCompletedNCT02472756Results posted
- Rituximab Therapy in Follicular Lymphoma in Combination With Chemotherapy - REFLECT 1CompletedNCT02461290Results posted
- Prospective Observational Study on the Management of Patients With Relapsed or Refractory Follicular Lymphoma (OLYMPE)CompletedNCT02316613Results posted
- A Study Evaluating the Safety and Efficacy of Venetoclax (GDC-0199) Plus Bendamustine + Rituximab (BR) in Comparison With BR or Venetoclax Plus Rituximab in Participants With Relapsed and Refractory Follicular Non-Hodgkin's Lymphoma (fNHL)CompletedNCT02187861Phase 2Results posted
- A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01691898Phase 1/2Results posted
- A Study of Obinutuzumab in Chinese Participants With CD20+ Malignant DiseaseCompletedNCT01680991Phase 1Results posted
- A Study to Investigate the Efficacy and Safety of Bendamustine Compared With Bendamustine+Obinutuzumab (GA101) in Participants With Rituximab-Refractory, Indolent Non-Hodgkin's Lymphoma (GADOLIN)CompletedNCT01059630Phase 3Results posted
- A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular LymphomaActive, not recruitingNCT04712097Phase 3
- A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular LymphomaActive, not recruitingNCT04246086Phase 1/2
- Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT03374137
- An Observational Study of MabThera/Rituxan (Rituximab) in Patients With Follicular LymphomaTerminatedNCT01609036
- A Pharmacokinetic Study of Subcutaneous and Intravenous Rituximab in Participants With Follicular LymphomaCompletedNCT00930514Phase 1
- An Observational Study of Treatment, Outcomes, and Prognosis in Patients With Follicular Non-Hodgkin's LymphomaCompletedNCT00097565